Richard B. Silverman

Richard B. Silverman is a Professor in the Department of Chemistry at Northwestern University. His research focuses on the rational design, synthesis, and molecular mechanisms of potential medicinal agents, particularly in the treatment of central nervous system disorders and cancer. His work involves enzyme inhibition, computer modeling, and collaborations in X-ray crystallography and preclinical studies. Silverman has contributed to the development of several drugs, including Lyrica, which is on the market, and others in clinical trials. His research has been published in prominent journals, and he has received numerous awards and honors for his contributions to chemistry and medicinal research.